3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
11
Brain Neoplasms
3
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Medulloblastoma
2
Leukemia, Myeloid, Acute
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Xanthomatosis, Cerebrotendinous
1
Vaccinia
1
Uveal Melanoma
1
Transplant-Related Hematologic Malignancy
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Resectable Esophageal Cancer
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Oligodendroglioma
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Influenza, Human
1
Interventions
Temozolomide
15
Radiotherapy
10
Radiation
8
Magnetic Resonance Spectroscopy
7
pembrolizumab
5
Specimen Handling
5
Ipilimumab
3
atezolizumab
2
Photons
2
Nivolumab
2
Biopsy
2
veliparib
1
selinexor
1
sargramostim
1
plerixafor
1
peposertib
1
pazopanib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
montanide ISA 51
1
liposomal doxorubicin
1
gosha-jinki-gan
1
fluorodopa F 18
1
ferric pyrophosphate
1
efineptakin alfa
1
cemiplimab
1
cabozantinib
1
balstilimab
1
abexinostat
1
X-Rays
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
1 year
×
Clear all
No trials found.